Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
PR Newswire•17/11/2026•16:53 ET
0
Key Highlights
- ➤Ozekibart combination achieves 62.7% ORR in relapsed/refractory Ewing sarcoma
- ➤Combination delivers 86.3% DCR among response-evaluable patients
- ➤Median progression-free survival reaches 6.0 months
- ➤18 patients experience durable clinical benefit exceeding six months
- ➤FDA accepts Inhibrx’s biologics license application for conventional chondrosarcoma
Expert Statements
Mark Lappe, Chief Executive Officer of Inhibrx
“The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas.”
Mark Lappe, Chief Executive Officer of Inhibrx
“In relapsed or refractory Ewing sarcoma, achieving a 62.7% overall response rate, an 86.3% disease control rate, and clinically meaningful durability is particularly compelling in a population that has exhausted effective options.”
Mark Lappe, Chief Executive Officer of Inhibrx
“Based on these results, we intend to rapidly advance our plans with the goal of allowing patients access as soon as possible.”
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma PR Newswire
- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR; - 86.3% DCR, with durable responses observed in heavily pretreated patients
Get started
Create a free account to read the full story.
